{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:05:40Z","timestamp":1787313940567,"version":"build-2736575974"},"reference-count":40,"publisher":"Jaypee Brothers Medical Publishing","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.59556\/japi.73.1181","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T06:14:16Z","timestamp":1760508856000},"page":"e55-e59","source":"Crossref","is-referenced-by-count":1,"title":["What Makes Cefpodoxime an Empiric Drug of Choice to Treat Lower Respiratory Tract Infections, including Acute Exacerbation of Chronic Obstructive Pulmonary Disease, in the Real-world Setting in India?"],"prefix":"10.59556","volume":"73","author":[{"given":"Deepak","family":"Talwar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agam","family":"Vora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandrakant","family":"Tarke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asmita","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naveed Nazir","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Dalal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2914","reference":[{"issue":"(4):","key":"key20251015061413_B1","doi-asserted-by":"crossref","first-page":"549\u2013","DOI":"10.1513\/pats.200709-148ET","article-title":"Comorbidities in chronic obstructive pulmonary disease.","volume":"5","author":"Chatila","year":"2008;","journal-title":"Proc Am Thorac Soc"},{"issue":"(2):","key":"key20251015061413_B2","doi-asserted-by":"crossref","first-page":"e0317592.","DOI":"10.1371\/journal.pone.0317592","article-title":"Mortality trends and disparities for coexisting chronic obstructive pulmonary disease and cardiovascular disease: a retrospective analysis of deaths in the United States from 1999\u20132020.","volume":"20","author":"Goyal","year":"2025;","journal-title":"PLoS One"},{"issue":"(5):","key":"key20251015061413_B3","doi-asserted-by":"crossref","first-page":"1801261.","DOI":"10.1183\/13993003.01261-2018","article-title":"What is a COPD exacerbation? Current definitions, pitfalls, challenges, and opportunities for improvement.","volume":"52","author":"Kim","year":"2018;","journal-title":"Eur Respir J"},{"issue":"(1):","key":"key20251015061413_B4","first-page":"37\u2013","article-title":"Cefpodoxime in the outpatient treatment of lower respiratory tract infections.","volume":"1","author":"Minov","year":"2021;","journal-title":"Acad Med J"},{"key":"key20251015061413_B5","article-title":"Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2025 REPORT).","author":"Committee"},{"key":"key20251015061413_B6","volume-title":"StatPearls [Internet].","author":"Widysanto","year":"2025."},{"key":"key20251015061413_B7","doi-asserted-by":"crossref","first-page":"520\u2013","DOI":"10.1136\/thoraxjnl-2019-214484","article-title":"Acute exacerbations of chronic obstructive pulmonary disease: in search of diagnostic biomarkers and treatable traits.","volume":"75:","author":"Mathioudakis","year":"2020;","journal-title":"Thorax"},{"issue":"(3):","key":"key20251015061413_B8","doi-asserted-by":"crossref","first-page":"218\u2013","DOI":"10.1513\/pats.200510-114SF","article-title":"Impact of chronic obstructive pulmonary disease exacerbations on patients and payers.","volume":"3","author":"Wedzicha","year":"2006;","journal-title":"Proc Am Thorac Soc"},{"issue":"(12):","key":"key20251015061413_B9","doi-asserted-by":"crossref","first-page":"1128\u2013","DOI":"10.1056\/NEJMoa0909883","article-title":"Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. Susceptibility to exacerbation in chronic obstructive pulmonary disease.","volume":"363","author":"Hurst","year":"2010;","journal-title":"N Engl J Med"},{"key":"key20251015061413_B10","doi-asserted-by":"crossref","first-page":"1579\u2013","DOI":"10.2147\/COPD.S106160","article-title":"Acute exacerbation of COPD: is it the \u201cstroke of the lungs\u201d?","volume":"11:","author":"Hillas","year":"2016;","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"(10):","key":"key20251015061413_B11","doi-asserted-by":"crossref","first-page":"e109721.","DOI":"10.1371\/journal.pone.0109721","article-title":"Predictors of exacerbations in chronic obstructive pulmonary disease\u2014results from the Bergen COPD cohort study.","volume":"9","author":"Huseb\u00f8","year":"2014;","journal-title":"PLoS One"},{"issue":"(116):","key":"key20251015061413_B12","doi-asserted-by":"crossref","first-page":"113\u2013","DOI":"10.1183\/09059180.00002610","article-title":"Impact of exacerbations on COPD.","volume":"19","author":"Anzueto","year":"2010;","journal-title":"Eur Respir Rev"},{"key":"key20251015061413_B13","doi-asserted-by":"crossref","first-page":"702\u2013","DOI":"10.1136\/heartjnl-2023-323487","article-title":"Heightened long-term cardiovascular risks after exacerbation of chronic obstructive pulmonary disease.","volume":"110:","author":"Hawkins","year":"2024;","journal-title":"Heart"},{"issue":"(1):","key":"key20251015061413_B14","first-page":"00756\u2013","article-title":"Treatable cardiac disease in hospitalised COPD exacerbations.","volume":"7","author":"Leong","year":"2021;","journal-title":"ERJ Open Res"},{"issue":"(1):","key":"key20251015061413_B15","doi-asserted-by":"crossref","first-page":"40\u2013","DOI":"10.4103\/0253-7613.75667","article-title":"Clinical effectiveness and safety of gemifloxacin versus cefpodoxime in acute exacerbation of chronic bronchitis: a randomized, controlled trial.","volume":"43","author":"Chatterjee","year":"2011;","journal-title":"Indian J Pharmacol"},{"issue":"(4):","key":"key20251015061413_B16","doi-asserted-by":"crossref","first-page":"S19\u2013","DOI":"10.1097\/00006454-199504001-00004","article-title":"Multicenter trial of cefpodoxime proxetil vs. amoxicillin-clavulanate in acute lower respiratory tract infections in childhood. International Study Group.","volume":"14","author":"Klein","year":"1995;","journal-title":"Pediatr Infect Dis J"},{"issue":"(10):","key":"key20251015061413_B17","doi-asserted-by":"crossref","first-page":"989\u2013","DOI":"10.1080\/17425255.2024.2391389","article-title":"Clinical pharmacokinetics of cefpodoxime: a systematic review.","volume":"20","author":"Farooq","year":"2024;","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"(11):","key":"key20251015061413_B18","doi-asserted-by":"crossref","first-page":"1840\u2013","DOI":"10.1016\/S0149-2918(02)80083-2","article-title":"Cefditoren pivoxil versus cefpodoxime proxetil for community-acquired pneumonia: results of a multicenter, prospective, randomized, double-blind study.","volume":"24","author":"van Zyl","year":"2002;","journal-title":"Clin Ther"},{"issue":"(E):","key":"key20251015061413_B19","doi-asserted-by":"crossref","first-page":"63\u2013","DOI":"10.1093\/jac\/26.suppl_E.63","article-title":"Efficacy and tolerance of cefpodoxime proxetil compared with co-amoxiclav in the treatment of exacerbations of chronic bronchitis.","volume":"26","author":"Periti","year":"1990;","journal-title":"J Antimicrob Chemother"},{"key":"key20251015061413_B20","unstructured":"Cefpodoxime Prescribing Information. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/065462s005lbl.pdf Accessed June 6, 2025."},{"key":"key20251015061413_B21","article-title":"Community pharmacy reports of potential QTc-prolonging drug-interactions involving fluoroquinolones or macrolides: a multi-incident analysis.","author":"Tahavori","year":"2015.","journal-title":"ISMP Canada"},{"issue":"(11);","key":"key20251015061413_B22","first-page":"250\u2013","article-title":"Physicians' Perspectives and Opinion towards the Utilization of Cefpodoxime Proxetil: a nationwide study.","volume":"14","author":"Janarthanan","year":"2024;","journal-title":"Int J Toxicol Pharmacol Res"},{"issue":"(1):","key":"key20251015061413_B23","first-page":"1\u2013","article-title":"Patterns of recurrence and antimicrobial management in respiratory infections: a real-world retrospective study.","volume":"6","author":"Talwar","year":"2021;","journal-title":"J Pulmon Respir Sci"},{"issue":"(5):","key":"key20251015061413_B24","doi-asserted-by":"crossref","first-page":"353\u2013","DOI":"10.1007\/BF01645369","article-title":"In vitro evaluation of cefpodoxime, a new oral cephalosporin of the third generation.","volume":"19","author":"Bauernfeind","year":"1991;","journal-title":"Infection"},{"issue":"(5):","key":"key20251015061413_B25","doi-asserted-by":"crossref","first-page":"889\u2013","DOI":"10.2165\/00003495-199244050-00011","article-title":"Cefpodoxime proxetil: a review of its antibacterial activity, pharmacokinetic properties and therapeutic potential.","volume":"44","author":"Frampton","year":"1992;","journal-title":"Drugs"},{"issue":"(E):","key":"key20251015061413_B26","doi-asserted-by":"crossref","first-page":"41\u2013","DOI":"10.1093\/jac\/26.suppl_E.41","article-title":"Concentrations of cefpodoxime in plasma and pleural fluid after a single oral dose of cefpodoxime proxetil.","volume":"26","author":"Dumont","year":"1990;","journal-title":"J Antimicrob Chemother"},{"issue":"(9):","key":"key20251015061413_B27","first-page":"815\u2013","article-title":"Comparative trial of the clinical efficacy and tolerance of cefatrizine (Cefaperos) and cefpodoxime proxetil (Orelox) in superinfections of chronic obstructive bronchopneumopathies in adults in urban practice.","volume":"43","author":"Brambilla","year":"1995;","journal-title":"Pathol Biol (Paris)"},{"issue":"(6):","key":"key20251015061413_B28","doi-asserted-by":"crossref","first-page":"1545\u2013","DOI":"10.1128\/AAC.40.6.1545","article-title":"Activity of once-daily cefpodoxime regimens against Haemophilus influenzae and Streptococcus pneumoniae with an in vitro pharmacodynamic chamber model.","volume":"40","author":"Garrison","year":"1996;","journal-title":"Antimicrob Agents Chemother"},{"issue":"(1):","key":"key20251015061413_B29","first-page":"21\u2013","article-title":"Observational study of the tolerance and effectiveness of cefpodoxime-proxetil in general practice.","volume":"120","author":"Hanke","year":"2002;","journal-title":"Fortschr Med Orig"},{"issue":"(3):","key":"key20251015061413_B30","doi-asserted-by":"crossref","first-page":"266\u2013","DOI":"10.36488\/cmac.2023.3.266-276","article-title":"Oral third-generation cephalosporin cefpodoxime in the therapy of respiratory infections.","volume":"25","author":"Stetsiouk","year":"2023;","journal-title":"Clin Microbiol Antimicrob Chemother"},{"issue":"(3):","key":"key20251015061413_B31","doi-asserted-by":"crossref","first-page":"547\u2013","DOI":"10.18203\/2319-2003.ijbcp20150037","article-title":"An epidemiological survey to assess the clinical use of cephalosporins in community-acquired respiratory tract infections.","volume":"4","author":"Sobti","year":"2015;","journal-title":"Int J Basic Clin Pharmacol"},{"issue":"(4):","key":"key20251015061413_B32","doi-asserted-by":"crossref","first-page":"190\u2013","DOI":"10.1007\/s15010-006-5120-x","article-title":"Moxifloxacin versus standard therapy in patients with pneumonia hospitalized after the failure of preclinical anti-infective treatment.","volume":"34","author":"Wenisch","year":"2006;","journal-title":"Infection"},{"issue":"(5):","key":"key20251015061413_B33","doi-asserted-by":"crossref","first-page":"121S\u2013","DOI":"10.1378\/chest.121.5_suppl.121S","article-title":"COPD: epidemiology, prevalence, morbidity and mortality, and disease heterogeneity.","volume":"121","author":"Mannino","year":"2002;","journal-title":"Chest"},{"issue":"(1):","key":"key20251015061413_B34","first-page":"8\u2013","article-title":"Drug utilization pattern of antibacterials used in ear, nose and throat outpatient and inpatient departments of a university hospital at New Delhi, India.","volume":"2","author":"Ain","year":"2010;","journal-title":"J Pharm Bioallied Sci"},{"issue":"(6):","key":"key20251015061413_B35","first-page":"FC01\u2013","article-title":"Comparison of efficacy and safety of cefpodoxime and amoxicillin-clavulanate potassium in paediatric acute otitis media in children below two years: a prospective longitudinal study.","volume":"11","author":"Ghosh","year":"2017;","journal-title":"J Clin Diagn Res"},{"issue":"(4):","key":"key20251015061413_B36","doi-asserted-by":"crossref","first-page":"493\u2013","DOI":"10.1016\/j.cjco.2025.01.001","article-title":"The intersection of chronic obstructive pulmonary disease and cardiovascular disease: recent insights in a challenging area.","volume":"7","author":"Heffernan","year":"2025;","journal-title":"CJC Open"},{"issue":"(1\u20132):","key":"key20251015061413_B37","doi-asserted-by":"crossref","first-page":"123\u2013","DOI":"10.1016\/S0163-7258(02)00176-6","article-title":"Tumor necrosis factor-alpha in cardiovascular biology and the potential role for anti-tumor necrosis factor-alpha therapy in heart disease.","volume":"94","author":"Sack","year":"2002;","journal-title":"Pharmacol Ther"},{"issue":"(2):","key":"key20251015061413_B38","doi-asserted-by":"crossref","first-page":"143\u2013","DOI":"10.1016\/0732-8893(93)90025-3","article-title":"In vitro activity of cefpodoxime compared with other oral cephalosporins tested against 5556 recent clinical isolates from five medical centers.","volume":"17","author":"Sader","year":"1993;","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"(5):","key":"key20251015061413_B39","doi-asserted-by":"crossref","first-page":"370\u2013","DOI":"10.1007\/BF01645371","article-title":"Cefpodoxime: comparative antibacterial activity, influence of growth conditions, and bactericidal activity.","volume":"19","author":"Knothe","year":"1991;","journal-title":"Infection"},{"key":"key20251015061413_B40","first-page":"1\u2013","article-title":"Burden and regional disparities of chronic obstructive pulmonary disease in India: insights from the global burden of disease data and projections for future incidence.","author":"Kumar","year":"2025:","journal-title":"Expert Rev Respir Med"}],"container-title":["Journal of The Association of Physicians of India"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T06:14:20Z","timestamp":1760508860000},"score":1,"resource":{"primary":{"URL":"https:\/\/japi.org\/article\/japi-73-10-e55"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":40,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.59556\/japi.73.1181"],"URL":"https:\/\/doi.org\/10.59556\/japi.73.1181","relation":{},"ISSN":["0004-5772"],"issn-type":[{"value":"0004-5772","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]}}}